Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2016 (2016), Article ID 8175957, 3 pages
Case Report

Long-Term Treatment with Romidepsin in Patients with Peripheral T-Cell Lymphoma

1Hôpital de la Tour Unite d’Oncologie-Hematologie, Meyrin, Switzerland
2Viollier Weintraub, Geneva, Switzerland

Received 6 June 2016; Revised 22 July 2016; Accepted 2 August 2016

Academic Editor: Akimichi Ohsaka

Copyright © 2016 Claudius Irlé and Jonathan Weintraub. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive non-Hodgkin lymphomas. Angioimmunoblastic T-cell lymphoma (AITL) is a common subtype of PTCL, and patients with AITL typically have a poor prognosis with limited treatment options. Clinical studies have demonstrated the activity of romidepsin, a structurally unique, potent, bicyclic class 1 selective histone deacetylase inhibitor, in patients with relapsed or refractory AITL. In the case presented herein, we describe a patient treated with single-agent romidepsin at first diagnosis of AITL, resulting in complete remission for over 2 years and leading to the use of maintenance dosing. The patient eventually underwent a successful autologous stem cell transplant. This case illustrates the successful use of romidepsin for the long-term treatment of a patient with AITL in a clinical setting. Maintenance dosing may be an option for patients who have an extended response to romidepsin in order to optimize outcomes and to prolong time to the next subsequent line of therapy. In our case, the patient was able to remain in complete remission for more than 1 year while receiving maintenance dosing of romidepsin.